Dose-Response Relationship between Post-Progression Bevacizumab Exposure and Survival among Metastatic Colorectal Cancer Patients

被引:0
|
作者
Flick, E. Dawn [1 ]
Barr, Charles E. [1 ]
Fish, Susan M. [1 ]
Leon, Larry F. [1 ]
Mun, Yong [1 ]
Dalal, Darshan [1 ]
机构
[1] Genentech Inc, San Francisco, CA 94080 USA
关键词
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
520
引用
收藏
页码:244 / 245
页数:2
相关论文
共 50 条
  • [31] The impact of the type of progression on survival in patients with metastatic colorectal cancer
    Shibutani, M.
    Maeda, K.
    Nagahara, H.
    Fukuoka, T.
    Nakao, S.
    Matsutani, S.
    Kashiwagi, S.
    Hirakawa, K.
    Ohira, M.
    ANNALS OF ONCOLOGY, 2017, 28 : 48 - 48
  • [32] Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients
    Lobet, Sarah
    Paintaud, Gilles
    Azzopardi, Nicolas
    Passot, Christophe
    Caulet, Morgane
    Chautard, Romain
    Desvignes, Celine
    Capitain, Olivier
    Tougeron, David
    Lecomte, Thierry
    Ternant, David
    CLINICAL PHARMACOKINETICS, 2023, 62 (09) : 1263 - 1274
  • [33] Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients
    Sarah Lobet
    Gilles Paintaud
    Nicolas Azzopardi
    Christophe Passot
    Morgane Caulet
    Romain Chautard
    Céline Desvignes
    Olivier Capitain
    David Tougeron
    Thierry Lecomte
    David Ternant
    Clinical Pharmacokinetics, 2023, 62 : 1263 - 1274
  • [34] Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer-the Experience of a Tertiary Cancer Center
    Cainap, Calin
    Bochis, Ovidiu-Vasile
    Vlad, Catalin
    Popita, Raluca
    Achimas-Cadariu, Patriciu
    Havasi, Andrei
    Vidrean, Andreea
    Dranca, Alexandra
    Piciu, Andra
    Constantin, Anne-Marie
    Tat, Tiberiu
    Dana, Maniu
    Crisan, Ovidiu
    Cioban, Cosmin Vasile
    Balacescu, Ovidiu
    Coza, Ovidiu
    Balacescu, Loredana
    Marta, Monica Mihaela
    Bota, Madalina
    Cainap, Simona
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [35] Association of morphologic response with progression free survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: HGCSG0802.
    Yuki, Satoshi
    Nakatsumi, Hiroshi
    Hayashi, Hideyuki
    Fukushima, Hiraku
    Kato, Takashi
    Meguro, Takashi
    Nakamura, Michio
    Iwanaga, Ichiro
    Eto, Kazunori
    Sato, Atsushi
    Okuda, Hiroyuki
    Oba, Ayane
    Miyagishima, Takuto
    Muto, Osamu
    Yabusaki, Satoshi
    Miyamoto, Noriyuki
    Kudo, Kohsuke
    Sakamoto, Naoya
    Sakata, Yuh
    Komatsu, Yoshito
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [36] IS THERE A DOSE-RESPONSE RELATIONSHIP BETWEEN EXPOSURE TO INDOOR ALLERGENS AND SYMPTOMS OF ASTHMA
    PLATTSMILLS, TAE
    SPORIK, RB
    WHEATLEY, LM
    HEYMANN, PW
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1995, 96 (04) : 435 - 440
  • [37] Survival outcome of bevacizumab followed by cetuximab in metastatic colorectal cancer patients.
    Kataoka, Kozo
    Kanazawa, Akiyoshi
    Nakajima, Akio
    Hosogi, Hisahiro
    Kanaya, Seiitirou
    Kohno, Yukihiro
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [38] Does bevacizumab improve survival in patients with metastatic colorectal cancer treated with chemotherapy?
    Grothey, A
    NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (01): : 22 - 23
  • [39] Does bevacizumab improve survival in patients with metastatic colorectal cancer treated with chemotherapy?
    Axel Grothey
    Nature Clinical Practice Oncology, 2006, 3 : 22 - 23
  • [40] Impact of post-progression anti-vascular endothelial growth factor-containing therapy on survival in patients with metastatic colorectal cancer: Data from the PRIME study
    Peeters, M.
    Douillard, J. Y.
    Siena, S.
    Price, T.
    Tabernero, J.
    Sidhu, R.
    Braun, S.
    Davison, C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S18 - S18